Published in Health and Medicine Week, October 2nd, 2006
Presented at the 2006 Annual Congress of the European Respiratory Society, safety data collected since the original approval of Prolastin in 1987 now represent more than 18 years of clinical experience and 40,826 patient-years of exposure. Results demonstrate that Prolastin continues to be well tolerated with respect to drug interactions, overdose, and abuse potential.
Thomas Bernhardt, MD,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.